Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain.
Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration approved Spiriva Respimat (tiotropium bromide) inhalation spray as a treatment for bronchospasm associated with chronic obstructive pulmonary disease.
AbbVie on Thursday announced that the Food and Drug Administration approved Humira (adalimumab) as a treatment for pediatric Crohn's disease patients ages 6 years and older when other treatments haven't worked well enough.
Sandoz announced the launch of Kerydin (tavaborole) topical solution, 5% in the United States. Kerydin is the first oxaborole antifungal for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes, the company stated.